Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rocio Lledo‐Garcia"'
Autor:
Denis Menshykau, Jagdev Sidhu, Laura Shaughnessy, Rocio Lledo‐Garcia, Pinky Dua, Marie Teil, Akash Khandelwal
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 11, Pp 1904-1914 (2024)
Abstract Certolizumab pegol (CZP; CIMZIA™) is the only Fc‐free tumor necrosis factor inhibitor with data from a clinical study demonstrating no to minimal placental transfer. The pharmacokinetics (PK) of certolizumab pegol during pregnancy and po
Externí odkaz:
https://doaj.org/article/0ea6f96c831248acb8c94d0a71f46dd0
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 116-128 (2022)
Abstract Rozanolixizumab is a fully humanized high‐affinity anti‐human neonatal Fc receptor (FcRn) monoclonal antibody (mAb) that accelerates the removal of circulating immunoglobulin G (IgG), including pathogenic IgG autoantibodies, via the natu
Externí odkaz:
https://doaj.org/article/86e0c900926549b79d038e9285220507
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 116-128 (2022)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Rozanolixizumab is a fully humanized high‐affinity anti‐human neonatal Fc receptor (FcRn) monoclonal antibody (mAb) that accelerates the removal of circulating immunoglobulin G (IgG), including pathogenic IgG autoantibodies, via the natural lysos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785ae964dded5cd746279ed006bc0ad7
https://doi.org/10.1002/psp4.12739
https://doi.org/10.1002/psp4.12739
Autor:
Paul Atherfold, Hanna Hailu, Louis Christodoulou, Lena E. D’Hooghe, Bryan Smith, Helene Margaret Finney, Frank R. Brennan, Stevan Shaw, Kerry Louise Tyson, Daniel John Lightwood, Andrea Kiessling, Kevin Greenslade, Omar Qureshi, Lara Kevorkian, Rebecca Munro, Kate L. Dixon, Rocio Lledo-Garcia, Shauna West, Christoph Meier, Matthew C. Catley, Kaushik Sarkar, Alison Turner, Roohi Tewari, Sophie P. Shaw
Publikováno v:
mAbs
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), has been developed to reduce pathogenic IgG in autoimmune and alloimmune diseases. We document the antibody isolation and compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045641d5108e50151ed33d8046d2ce07
http://europepmc.org/articles/PMC6291300
http://europepmc.org/articles/PMC6291300
Autor:
Yoshiya Tanaka, Seiji Yoshizawa, Jing Shao, Takao Koike, Yoshinari Takasaki, Shinji Morimoto, Osamu Togo, Junichi Yamamoto, Kazuyoshi Saito, Rocio Lledo-Garcia, Mitsumasa Kishimoto, Hiroaki Niiro, Tomomi Tsuru, Tomoya Miyamura, Shuichiro Tatematsu
Publikováno v:
Modern Rheumatology. 26:87-93
Objectives: This 12-week, randomized, double-blind, placebo-controlled, multicenter phase 1/2 study (NCT01449071) assessed the safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef51ccf7b6979d7edc0f33cedd575a6e
https://doi.org/10.3109/14397595.2015.1079292
https://doi.org/10.3109/14397595.2015.1079292
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Autor:
Peter Kiessling, Bryan Smith, Graham Price, Grant Langdon, Emma Jones, Frank R. Brennan, Muhammad Bari, Louis Christodoulou, Ian White, Diep Tran, Rocio Lledo-Garcia, Shikiko Watanabe, Stephen Jolles
Publikováno v:
Science translational medicine. 9(414)
Pathogenic immunoglobulin G (IgG) autoantibodies characterize some human autoimmune diseases; their high concentration and long half-life are dependent on recycling by the neonatal Fc receptor (FcRn). Inhibition of FcRn is an attractive new treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f716f622e05da50694895fa11f94ad3e
https://pubmed.ncbi.nlm.nih.gov/29461460
https://pubmed.ncbi.nlm.nih.gov/29461460
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 39(2)
The aim of this study was to quantify the intestinal and hepatic first-pass loss of saquinavir and to assess the effect of coadministration of ritonavir on this first-pass loss. Single doses of 12, 24, and 48 mg of saquinavir and a dose of 24 mg of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b77dc1c57fb218e28f0be26b7bd389
https://pubmed.ncbi.nlm.nih.gov/20978105
https://pubmed.ncbi.nlm.nih.gov/20978105
Publikováno v:
Annals of the Rheumatic Diseases. 73:526.1-526
Background Treatment with epratuzumab, a humanized monoclonal antibody targeting CD22 on B cells, has been associated with improvements in disease activity in patients (pts) with moderate-to-severe systemic lupus erythematosus (SLE) with an acceptabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef68f1829a0f55f89fcc93918a7c117b
https://doi.org/10.1136/annrheumdis-2014-eular.1754
https://doi.org/10.1136/annrheumdis-2014-eular.1754